公开(公告)号：US20210196793A1

公开(公告)日：2021-07-01

申请号：US17269788

申请日：2019-08-16

申请人： CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

发明人： Diana GARCIA DEL BARCO HERRERA ,  Gerardo Enrique GUILLÉN NIETO ,  Mariela VAZQUEZ CASTILLO ,  Francisco HERNÁNDEZ BERNAL ,  Tatiana ZALDIVAR VAILLANT ,  Pablo Arsenio DIAZ REYES ,  ldania Caridad BALADRON CASTRILLO ,  Vladimir Armando BESADA PÉREZ ,  Sonia GONZALEZ BLANCO ,  Jorge Amador BERLANGA ACOSTA ,  Héctor Manuel PÉREZ SAAD

IPC分类号： A61K38/18 ,  A61P25/00 ,  A61K38/27

摘要： The invention discloses a pharmaceutical combination comprising epidermal growth factor (EGF) and the hexapeptide secretagogue GHRP6, useful for the restoration of brain damage, by stimulating mechanisms of differentiation and neuronal specialization in undifferentiated cells residing in the central nervous system or in neuronal cells. The invention also encompasses the use of the above mentioned biomolecules in the manufacture of a pharmaceutical combination for the restoration of brain damage. In addition, the invention provides a method of restoring brain damage in which a therapeutically effective amount of a pharmaceutical combination comprising EGF and GHRP6 is administered to a patient in need thereof. The efficacy of the pharmaceutical combination has a broad therapeutic window: it is independent of whether the pharmacological intervention occurs in the first or further hours after the brain damage, which broadens the therapeutic window.

公开(公告)号：US20200297840A1

公开(公告)日：2020-09-24

申请号：US16088188

申请日：2017-03-14

申请人： CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA

发明人： Julio César AGUILAR RUBIDO ,  Yadira LOBAINA MATO ,  Enrique IGLESIAS PEREZ ,  Eduardo PENTÓN ARIAS ,  Gerardo Enrique GUILLÉN NIETO ,  Jorge Agustín AGUIAR SANTIAGO ,  Sonia GONZALEZ BLANCO ,  Jorge VALDES HERNANDEZ ,  Mariela VAZQUEZ CASTILLO

IPC分类号： A61K39/29 ,  A61P31/20 ,  A61K39/39

摘要： This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.